RxDoctor Payments Data

Andrew Mrugala, MD

Family Medicine · Pooler, GANPI 1518316207

Payments from drug & device makers

$8,992in general payments, 2019–2025

Across 551 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$983
  • Pfizer$805
  • AstraZeneca$694
  • AbbVie$617
  • Amgen$550
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,992 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$183,791
Medicare patients
420
Services billed
2,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide163$179,467
OzempicSemaglutide75$108,956
EliquisApixaban104$98,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$85,721
Trijardy XrEmpaglifloz/Linaglip/Metformin60$80,367
GlyxambiEmpagliflozin/Linagliptin40$62,491
Soliqua 100-33Insulin Glargine/Lixisenatide54$59,717
TrulicityDulaglutide46$57,261
FarxigaDapagliflozin Propanediol36$45,054
Synjardy XrEmpagliflozin/Metformin Hcl17$27,759
JardianceEmpagliflozin26$24,030
RybelsusSemaglutide11$21,421
Xigduo XrDapaglifloz Propaned/Metformin15$17,629
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med342$14,870
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$983$236,728209 claims
Boehringer IngelheimTrijardy Xr, Glyxambi, Synjardy Xr, Jardiance, Combivent Respimat$514$203,768158 claims
Novo NordiskOzempic, Rybelsus$1,402$130,37786 claims
PfizerEliquis$805$98,336104 claims
GSKTrelegy Ellipta, Breo Ellipta$286$94,454100 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$17$59,71754 claims
AstraZenecaFarxiga, Breztri Aerosphere$694$58,50657 claims
MerckJanuvia$212$10,57415 claims
AbbVieSynthroid$617$3,80653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Pooler

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →